Market OpportunityBel-sar could become the first approved treatment for primary choroidal melanoma, representing a significant market opportunity.
Regulatory ConfidenceThe FDA's special protocol assessment agreement for CoMpass indicates a stable trial design, increasing confidence in bel-sar's regulatory approval process.
Trial Design And ExecutionThe simplified primary endpoint in the Phase 3 trial of bel-sar is designed to facilitate smoother regulatory submissions to the FDA and EMA.